The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran.
The medicine is intended to treat a rare genetic condition called acute hepatic porphyria that can cause attacks of severe abdominal pain. The drug, which will be branded as Givlaari, will cost $575,000 per year, the company announced Wednesday; after discounts, it expects the average price to be $442,000 per year. Each vial of the drug will cost $39,000.
About the Author Reprints
What is the point of developing drugs NOBODY can afford?
This is a corporate greed at it’s best.
OMG!